Health Catalyst, Inc. (NASDAQ:HCAT) Given Average Rating of “Moderate Buy” by Brokerages

Health Catalyst, Inc. (NASDAQ:HCAT) has been given a consensus recommendation of “Moderate Buy” by the ten brokerages that are currently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $8.00.

Several equities research analysts have recently issued reports on HCAT shares. KeyCorp lowered their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Wednesday, April 16th. Stifel Nicolaus upped their price target on Health Catalyst from $5.00 to $5.50 and gave the stock a “hold” rating in a research report on Thursday, May 8th. Evercore ISI downgraded shares of Health Catalyst from an “outperform” rating to an “inline” rating in a research report on Wednesday, April 9th. Stephens reduced their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday, March 6th. Finally, Royal Bank of Canada dropped their target price on Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating on the stock in a report on Thursday, February 27th.

Health Catalyst Trading Up 0.5%

NASDAQ HCAT opened at $3.98 on Friday. The stock’s 50-day moving average is $3.94 and its 200-day moving average is $5.27. Health Catalyst has a one year low of $3.49 and a one year high of $9.24. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The firm has a market cap of $277.01 million, a P/E ratio of -2.95 and a beta of 1.53.

Institutional Trading of Health Catalyst

Several institutional investors and hedge funds have recently bought and sold shares of the business. Legato Capital Management LLC increased its holdings in shares of Health Catalyst by 3.7% during the 4th quarter. Legato Capital Management LLC now owns 87,992 shares of the company’s stock worth $622,000 after acquiring an additional 3,171 shares during the last quarter. Martin & Co. Inc. TN lifted its holdings in Health Catalyst by 80.0% during the 4th quarter. Martin & Co. Inc. TN now owns 490,998 shares of the company’s stock valued at $3,471,000 after purchasing an additional 218,293 shares during the last quarter. Impax Asset Management Group plc boosted its position in Health Catalyst by 7.7% during the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock worth $19,442,000 after purchasing an additional 195,525 shares during the period. Raymond James Financial Inc. bought a new position in Health Catalyst during the fourth quarter worth $2,044,000. Finally, AlphaQuest LLC increased its holdings in shares of Health Catalyst by 1,989.8% in the fourth quarter. AlphaQuest LLC now owns 87,395 shares of the company’s stock valued at $618,000 after purchasing an additional 83,213 shares during the last quarter. Institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.